AAV gene therapy for HoFH: cholesterol reduction by 97.5% in clinical trial
New AAV8 gene therapy NGGT006 for homozygous familial hypercholesterolemia reduced LDL-C by 97.5% in 3 weeks. Effect persists for 52 weeks. Find out who is eligible for treatment.
